Danish reimbursement committee submits diabetes reassessment proposal for feedback
The Danish Medicines Agency’s committee responsible for recommending what medicines gain rebates is looking into diabetes medicines – excluding insulin. A hearing round for industry feedback is slated to end early next year.
by albert rønning-andersson, translated by daniel pedersen
In March, the Danish Medicines Agency chose to go down a different path from what its reimbursement committee had recommended in a reassessment of the reimbursement of insulin prescribed to treat diabetes.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly to double Mounjaro production
For subscribers
